Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

详细信息    查看全文

• 作者：Roberto Sorio^a ; ^{rsorio@cro.it} ; Cé ; lia Roemer-Becuwe^b ; Felix Hilpert^c ; Emma Gibbs^d ; Yolanda Garcí ; a^e ; Janne Kaern^f ; Manon Huizing^g ; Petronella Witteveen^h ; Flora Zagouriⁱ ; David Coeffic^j ; Hans-Joachim Lü ; ck^k ; Antonio Gonzá ; lez-Martí ; n^l ; Gunnar Kristensen^m ; Charles-Briac Levaché ; ⁿ ; Chee Khoon Lee^d ; Val Gebski^d ; Eric Pujade-Lauraine^o ; on behalf of the AURELIA Investigators
• 关键词：Elderly ; Bevacizumab ; Ovarian cancer ; Platinum resistant ; Patient-reported outcomes
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：65-71
• 全文大小：426 K
• 卷排序：144

文摘

The PFS and response rate benefit from bevacizumab were similar regardless of age. Grade&#xA0;≥ 3 hypertension was more common with bevacizumab in older vs younger patients. Thromboembolic events were not increased with bevacizumab in patients ≥ 65 vs < 65 years. In older patients, no PRO benefit was seen with bevacizumab versus chemotherapy alone.